ea0081ep221 | Calcium and Bone | ECE2022
Karimian Negar
, Powell Christine
, Shih Fei
Objectives: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder caused by activin receptor-like kinase-2/activin A receptor type 1 (ALK2/ACVR1) mutation and characterized by heterotopic ossification (HO) inducing progressive restriction of mobility. IPN60130 is a selective ALK2/ACVR1 inhibitor being investigated for the treatment of FOP.1 Here, we describe methodology of the FALKON trial (NCT05039515) designed to compare efficacy a...